

Form PTO-1449
(MODIFIED)U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE

ATTY. DOCKET NO.

355908-3303

SERIAL NO.

10/502,149

APPLICANT

Anthony E. BOLTON, et al

FILING DATE

7/19/2004

GROUP ART UNIT

Not Yet Assigned

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

U.S. PATENT DOCUMENTS

INITIAL	REF	DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE IF APPROPRIATE

FOREIGN PATENT DOCUMENTS

	REF	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION	
							YES	NO
/MH/	B1	WO01/66785	9/13/2001	WIPO				

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

/MH/	C1	Fadok et al. "A receptor for phosphatidylserine-specific clearance of apoptotic cells" <i>Nature</i> 405:85-90 (2000)						
/MH/	C2	Scott, Rona, et al. "Phagocytosis and clearance of apoptotic cells is mediated by MER" <i>Nature</i> 411:207 (2001)						
/MH/	C3	Griffin, WST, et al. "Brain interleukin 1 and S-100 immunoreactivity are elevated in Down Syndrome and Alzheimer Disease" <i>Proceedings of the National Academy of Sciences USA</i> 86:7611-7615 (1989)						
/MH/	C4	Mogi, M. Interleukin (IL)-1 beta, IL-1, IL-4, IL-6 and transforming growth factor-alpha levels are elevated in ventricular cerebrospinal fluid in juvenile parkinsonism and Parkinson's Disease" <i>Neuroscience Letters</i> 211:13-16 (1996)						
/MH/	C5	Murray et al. "Evidence that increase hippocampal expression of the cytokine interleukin-1 β is a common trigger for age and stress-induced impairments in long-term potentiation" <i>J. Neuroscience</i> 18:2974-2981 (1998)						
/MH/	C6	Bliss et al. "A synaptic model of memory: long-term potentiation in the hippocampus" <i>Nature</i> 361:31-39 (1993)						


EXAMINER

/Maher Haddad/

DATE CONSIDERED

04/17/2007

- * EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include any copy of this form with next communication to applicant.

Form PTO-1449 (MODIFIED)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO. 355908-3303		SERIAL NO. 10/502,149	
 <p style="text-align: center;">INFORMATION DISCLOSURE CITATION</p> <p style="text-align: center;">(Use several sheets if necessary)</p>				APPLICANT Anthony E. BOLTON, et al			
				FILING DATE 7/19/2004		GROUP ART UNIT Not Yet Assigned	
U.S. PATENT DOCUMENTS							
EXAMINER INITIAL	REF	DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE IF APPROPRIATE
/MH/	A1	5,840,691	11/24/1998	Furcht et al.	<u> </u>		
FOREIGN PATENT DOCUMENTS							
	REF	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION YES NO
/MH/	B1	EP0298820	1/11/1989	Europe [English Abstract]	<u> </u>		X
/MH/	B2	JP8183740	7/16/1996	Japan [English Abstract]	<u> </u>		X
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)							
/MH/	C1	Lestini et al. "Surface modification of liposomes for selective cell targeting in cardiovascular drug delivery" <i>Journal of Controlled Release</i> 78:235-247 (2002)					
/MH/	C2	Sjaastad et al. "Feedback regulation of cell-substratum adhesion by integrin-mediated intracellular Ca ²⁺ signaling" <i>Proc. Natl. Acad. Sci. USA</i> 91:8214-8218 (1994)					
/MH/	C3	Adderley et al. "Glycoprotein IIb/IIIa Antagonists Induce Apoptosis in Rat Cardiomyocytes by Caspase-3 Activation" <i>J. of Biological Chemistry</i> 275(8):5760-5766 (2000)					
/MH/	C4	Ito et al. "Tcell adherence and mucosal injury in ulcerative colitis: Involvement of integrin-fibronectin interaction in situ" <i>J. Gaster.</i> 30:70-72 (1995)					
EXAMINER /Maher Haddad/				DATE CONSIDERED 04/17/2007			
* EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include any copy of this form with next communication to applicant.							